Core Scientific Balance Sheet Health
Financial Health criteria checks 0/6
Core Scientific has a total shareholder equity of $-962.7M and total debt of $1.1B, which brings its debt-to-equity ratio to -110.1%. Its total assets and total liabilities are $2.3B and $3.3B respectively.
Key information
-110.14%
Debt to equity ratio
US$1.06b
Debt
| Interest coverage ratio | n/a |
| Cash | US$311.38m |
| Equity | -US$962.74m |
| Total liabilities | US$3.31b |
| Total assets | US$2.35b |
Recent financial health updates
Recent updates
CORZ: AI Hosting Ramp And Power Buildout Are Expected To Drive Upside
Analysts have adjusted the Core Scientific fair value estimate from $37.43 to $35.65, reflecting updated assumptions around higher projected revenue growth and profit margins, along with a lower future P/E multiple and a slightly refined discount rate based on recent research highlighting progress in AI hosting capacity, lease expectations, and HPC expansion. Analyst Commentary Recent Street research points to generally constructive sentiment around Core Scientific, with several bullish analysts refining models as new information comes through on AI hosting progress, lease timing, and high performance computing capacity.
CORZ: AI Hosting Contracts And Power Expansion Will Drive Future Upside
Analysts have raised their blended price target on Core Scientific by a few dollars, placing it in the low to mid $20s. They cite progress on AI hosting contracts, expanded power capacity, and an ongoing shift in the power portfolio from Bitcoin mining toward high performance compute.CORZ: AI Hosting Shift And Lease Pipeline Will Drive Future Upside
Analysts have nudged the Core Scientific price target slightly lower, with the updated fair value estimate moving from about $26.82 to $26.40. They are weighing higher projected revenue growth and profit margins against revised P/E assumptions and recent research highlighting organic growth plans, AI hosting expansion and an evolving lease pipeline.
CORZ: AI Hosting Expansion And Texas Power Capacity Will Drive Future Upside
Analysts lifted their Core Scientific fair value estimate to $20 from $17, pointing to progress on new Texas capacity, AI hosting expansion, and expectations around additional lease signings as key drivers behind the higher price target range across recent research updates. Analyst Commentary Street research on Core Scientific has been active, with several firms updating their views around the company’s shift toward AI and high performance compute hosting, the timing of new lease signings, and the evolving power portfolio.CORZ: Power Shift To High Performance Compute Will Support Future Contracts
Analysts have lifted their $-denominated price targets on Core Scientific, with one firm increasing its view by $6. They point to steadier discount rate assumptions, slightly higher projected revenue growth and margins, and a lower future P/E multiple supported by expectations for additional high performance compute contracts after the failed CoreWeave merger.CORZ: Power Footprint Conversion To High Performance Compute Will Drive Next Phase
Analysts have trimmed their fair value estimate for Core Scientific from US$37.71 to US$37.43, citing updated assumptions around discount rates, revenue growth, margins and future P/E after recent price target changes and research highlighting both regulatory risks for crypto and potential long term upside from high performance computing contracts. Analyst Commentary Recent Street research around Core Scientific has highlighted a mix of crypto related policy risk and optimism around the company’s push into high performance computing, with some research pointing to potential valuation upside if execution on new contracts goes to plan.CORZ: Future Compute Contracts And Crypto Exposure Balance Fair Opportunity And Risk
Narrative Update The analyst price target for Core Scientific has shifted from US$15.00 to US$17.00 as analysts factor in improved profit margin assumptions, a lower modeled discount rate, and recent research that points to potential value creation from the company pursuing high performance compute contracts following the terminated CoreWeave merger. Analyst Commentary Recent research coverage has shifted toward a more constructive tone on Core Scientific, with several firms lifting ratings and price targets following the terminated CoreWeave merger and increased focus on high performance compute opportunities.CORZ: Power Footprint And HPC Contracts Will Define Next Phase
Narrative Update: Core Scientific Analyst Price Target Move The analyst price target for Core Scientific has shifted from roughly US$23.00 to about US$37.71. Analysts attribute this change to the resolution of the CoreWeave merger overhang, a renewed focus on high performance compute colocation contracts, and the perceived value of the company’s power infrastructure.Core Scientific: Buying This AI Data Center Winner Into Recent Weakness
Dec 17CORZ: Standalone AI Power Pipeline Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Core Scientific by about $0.83 per share to $26.82, reflecting a slightly higher discount rate even as they highlight improved standalone prospects, reduced deal overhang, and stronger AI infrastructure optionality as key supports for the updated price target. Analyst Commentary Recent Street research reflects a largely constructive shift in sentiment on Core Scientific, with multiple firms raising ratings and price targets as the market pivots to a standalone, AI and high performance compute oriented narrative following the termination of the CoreWeave merger.CORZ: Terminated Merger Will Unlock New Upside With Power Pipeline Expansion
Analysts have modestly raised their price target for Core Scientific to $27 from $23, citing the terminated merger and increased confidence in the company’s standalone prospects as key factors supporting improved valuation. Analyst Commentary Recent street research reflects a range of perspectives on Core Scientific's prospects as a standalone company, especially after the terminated merger.CORZ: Standalone Operator Status Will Unlock New Upside This Year
Analysts have increased their fair value price target for Core Scientific from $25.25 to $27.65. They cite renewed confidence in the company's standalone prospects and the removal of merger-related overhangs as reasons for this adjustment.CORZ: Power Portfolio And AI Demand Will Unlock Substantial Upside
Core Scientific's analyst price target has increased significantly from $20.88 to $25.25 per share. This change reflects analysts' optimism following the terminated merger with CoreWeave and improved standalone growth prospects for the company.HPC Expansion And Diversified Contracts Will Create Future Resilience
Analysts have raised their price target for Core Scientific from $19.95 to $20.88 per share, citing strong sector momentum from major data center deals and an improved profit margin outlook. Analyst Commentary Analyst discussions surrounding Core Scientific have highlighted both promising industry dynamics and company-specific considerations that could influence future performance and valuation.HPC Expansion And Diversified Contracts Will Create Future Resilience
Analysts have raised their price target for Core Scientific from $19.05 to $19.95 per share, citing updated deal terms and ongoing re-evaluation of merger economics following CoreWeave's acquisition agreement. Analyst Commentary Analysts continue to weigh the implications of Core Scientific's pending acquisition by CoreWeave, with a mix of optimism for the company's positioning and caution regarding valuation and deal structure.HPC Expansion And Diversified Contracts Will Create Future Resilience
Consensus analyst price targets for Core Scientific have risen slightly to reflect the strategic value of its infrastructure assets highlighted by the announced CoreWeave acquisition, despite some uncertainty regarding realized shareholder value and potential downside to deal economics, resulting in a revised fair value of $19.05. Analyst Commentary The announced acquisition of Core Scientific by CoreWeave in an all-stock transaction prompted widespread price target reductions and downgrades to Neutral/Hold/Perform, reflecting diminished standalone upside and uncertainty regarding the ultimate value realized by Core Scientific shareholders.
HPC Expansion And Diversified Contracts Will Create Future Resilience
Reallocating resources from Bitcoin mining to HPC infrastructure could drive future growth amid rising data center demands and diversified clientele.The AI Awakening Of Core Scientific
Mar 18DeepSeek, Market Volatility, False Rumor Create Opportunity In Core Scientific
Mar 09Core Scientific: Higher Digital Asset Prices And Making Progress On Debt
Jan 12Core Scientific: HPC Pivot Begins To Bear Fruit
Oct 16Core Scientific: Deserves Better As HPC Moves Into High Gear
Aug 13Core Scientific: HPC Deals And A Buyout Offer
Jun 04Financial Position Analysis
Short Term Liabilities: CORZ has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CORZ has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CORZ has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CORZ's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CORZ has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CORZ has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.1% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 21:31 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Core Scientific, Inc. is covered by 21 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ramsey El-Assal | Barclays |
| Gautam Chhugani | Bernstein |
| Nicholas Giles | B. Riley Securities, Inc. |